View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 24, 2016updated 13 Jul 2022 10:15am

QLT ends enrolment for natural history study in patients with RP and LCA

Canadian-based biotechnology company QLT has completed enrolment in its natural history study in subjects with Inherited Retinal Disease (IRD), phenotypically diagnosed with Retinitis Pigmentosa (RP), or Leber Congenital Amaurosis (LCA), due to underlying Retinal Pigment Epithelial 65 protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT) gene mutations.

Canadian-based biotechnology company QLT has completed enrolment in its natural history study in subjects with Inherited Retinal Disease (IRD), phenotypically diagnosed with Retinitis Pigmentosa (RP), or Leber Congenital Amaurosis (LCA), due to underlying Retinal Pigment Epithelial 65 protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT) gene mutations.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The objective of the retrospective, uncontrolled, multicentre study is to collect data on the natural succession of the disease in subjects over time, from childhood through to adulthood.

The study involved both subjects who had previously received treatment in QLT-sponsored clinical trials with QLT’s synthetic oral retinoid product, QLT091001, and subjects who had not received any prior therapeutic treatment.

For subjects who had received treatment with QLT091001, the natural history study included a retrospective review of subjects’ medical records prior to and after treatment with QLT091001.

"The objective of the retrospective, uncontrolled, multicentre study is to collect data on the natural succession of the disease in subjects over time, from childhood through to adulthood."

QLT stated that historically, it has been accepted that subjects born with IRD due to RPE65 or LRAT gene mutations would be expected to show an overall decline in visual field and visual acuity, but at varying rates and over differing periods of time.

Moreover, these patients may also demonstrate growing retinal atrophy as the disease progresses.

The aims of the natural history study were to collect data from these patients retrospectively, but under a formal protocol, thereby providing an opportunity to better observe and understand the long-term natural disease progression of untreated patients.

The trial will also provide comparative data to further assess the extent that the treatment with QLT091001 may prolong or improve visual function, relative to the underlying natural disease progression in these subjects.

The multi-site study sought to enrol up to 60 subjects from established IRD patient populations at ten clinical study sites in Europe, the US and Canada.

Altogether, 59 patients were enrolled in the study, 25 of whom had participated in earlier clinical studies with QLT091001, and 34 of whom were treatment naive.

Data was gathered from patient records for several visual outcome measures, with particular reference to changes in visual field and visual acuity for individual subjects over various years, and in some cases, decades, often starting in childhood.

QLT has completed its preliminary analysis and believes that the data suggests that these patients, without other interventions, demonstrate a continuing decline in visual field and eventually visual acuity over time.

The company expects to present the results for discussion with selected national European Agencies, and later with the US FDA.

Additionally, QLT is planning to begin a pivotal, Phase III multi-centre, placebo-controlled, double-masked clinical study for this indication, potentially in the third quarter of this year.

The objective of this study will be to further evaluate the efficacy, with particular reference to changes in visual field and visual acuity, and safety of QLT091001, with a goal of supporting future applications for full approval of QLT091001, for this indication to the EMA and US FDA.

The pivotal trial is expected to enrol 48 patients at around 12 sites in the EU, the US and Canada.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena